Psynomics Announces Gene Tests for Psychiatric Bipolar Disorder
News Feb 05, 2008
Psynomics, Inc. has announced that two tests for bipolar disorder are available for purchase on its web-site, along with descriptions, references and instructions. Either patients or their physicians may order the simple, non-invasive kits to collect DNA samples from saliva and the results are reported confidentially to the patient’s physician.
According to Psynomics, doctors are constantly making diagnostic and treatment decisions based on limited and imperfect information. The tests are designed to provide objective data for use by doctors in combination with their other evaluations to arrive at a timely and accurate diagnosis of a patient’s condition and the right therapy.
A recent article in the magazine “Science”, reviewing the company and its science, announced that Psynomics was the first company to venture into the new field of psychiatric gene testing, the company says.
Psynome™ tests for two mutations of the GRK3 gene that have been associated with bipolar disorder in multiple studies of hundreds of patients and Psynome2™ tests for serotonin transporter (SSRI) response as a predictor of patient response to serotonin based drugs, the most commonly prescribed drug therapies in psychiatry today. Psynomics’ lab work is reproducible and performed in a CLIA and state regulated laboratory.
In addition to being the CSO of Psynomics and a professor of psychiatry at the University of California, San Diego, Dr. Kelsoe is also a practicing psychiatrist who sees and treats bipolar patients every week.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.